Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant 500 mg vs Anastrozole 1 mg in Postmenopausal HR-Positive Advanced Breast Cancer
jRCT1080221957Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Fulvestrant 500 mg arm with Anastrozole 1 mg arm (2 arms). Started Nov 2012; status: completed.
02
Drugs
fulvestrantanastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT1080221957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080221957.